Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 17, 2004
Last updated: February 20, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2005
  Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
No publications provided by AstraZeneca

Publications automatically indexed to this study by Identifier (NCT Number):